explore -WSS

explore

author：hotspot 2025-08-12 13:36:31 - browse：7965

Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Flu, Covid vaccination rates decline, new survey data show

focus

WSS

PBM reform efforts get punted in Congress

WHO recommends second malaria vaccine

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

The stability of $0 premiums in Medicare Advantage

Obesity drugs seen as possible treatment for liver disease MASH

hotspot

explore

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Lawsuit highlights wrinkle for disputes over surprise medical bills

Continuity nursing helped my family in our darkest PICU moments

Study points to new risk in gene therapy death of Terry Horgan

Wildfire smoke exposes gaps in outdoor worker protections

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

As demand for Covid shots wanes, Moderna seeks its next success

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare innovation center doesn’t save money, experts say

entertainment

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Medicare innovation center doesn’t save money, experts say

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Community Health Systems hospitals under DOJ investigation

He's a Nobel laureate. Critics say he was misleading on Covid

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

focus

leisure time

hotspot

knowledge